argenx SE

- The company ended the quarter with a strong cash balance of $4.9 billion, an increase of over $400 million since the beginning of the year. - They have significant financial flexibility to deploy capital for long-term growth. - Capital allocation priorities focus on maximizing the VYVGART commercial opportunity, advancing the pipeline, strengthening supply chain, and pursuing business development. - There is no specific mention of any current or planned fundraising through debt or equity in the provided excerpts. - The company is investing from a position of financial strength and profitability, suggesting no immediate need for external fundraising.

- Increased R&D expenses driven by CMC investments to support expected launch of VYVGART subcutaneous auto-injector in 2027. - Continued development of efgartigimod across several indications and advancing pipeline assets. - Strategic investments focused on delivering long-term growth through innovation and transformational outcomes for patients. - Strong cash position ($4.9 billion) enables significant flexibility to deploy capital for: - Maximizing VYVGART commercial opportunity, - Advancing pipeline, - Strengthening supply chain, - Pursuing business development to source novel biology for long-term growth. - Investment in novel biology through strategic equity investment in Forte and options like Tensegrity to build pipeline for transformative outcomes. - Progressing manufacturing preparations for auto-injector production and approval targeting 2027 launch.

- Continued strong momentum and growth expected for VYVGART across MG and CIDP indications, with new patient demand among the highest ever in Q1 2026. - Expansion into broader MG populations including seronegative, ocular, and pediatric segments anticipated to drive growth. - Significant opportunity ahead as nearly 80% of MG patients are not yet on biologics. - Growth catalyzed by early-line adoption; 4 out of 5 healthcare providers prefer VYVGART as the first biologic in generalized MG. - Pipeline advancements including empasiprubart for MMN and potential launches in autoimmune myositis and Sjogren’s expected to contribute medium-term growth. - Investment in novel biology and strategic partnerships to sustain long-term growth and diversify revenue streams. - Operating leverage and margin expansion expected quarter-over-quarter and year-over-year, supported by high gross margins (~90%) and ongoing commercialization scale-up.

- Operating profit for Q1 2026 was $394 million with a 30% operating margin, representing 183% year-over-year growth. - Revenue growth is exceeding operating expense growth, leading to continued margin expansion and operating leverage as VYVGART scales. - The company expects margin expansion every quarter, year-over-year, supporting both innovation investment and profitability. - Strong cash balance ($4.9 billion) provides flexibility for capital allocation towards maximizing VYVGART commercial opportunity, pipeline advancement, supply chain strengthening, and business development. - Full-year 2026 sales expectations for VYVGART remain unchanged with strong underlying momentum. - The company aims to grow patient numbers (2.5x by 2030), increase approved indications (3x), and advance five molecules to late-stage development to ensure medium and long-term growth.

The provided document does not explicitly mention current or expected orderbook or pending orders data. However, relevant related commercial insights include: - New patient starts for VYVGART were among the highest since launch, indicating strong demand. - Over 5,000 neurologists are prescribing VYVGART in the U.S., with a doubling in the prescriber base since CIDP launch. - Market research shows 4 out of 5 healthcare providers prefer VYVGART as the first targeted biologic in generalized Myasthenia Gravis (gMG). - Prefilled syringe (PFS) introduction has materially increased demand, with 68% of PFS patients being new to VYVGART since launch. - New patient demand continues to build across indications, driving consistent quarter-over-quarter patient growth. - No direct mention of order backlog, but strong commercial momentum and expanding prescriber base indicate robust ongoing demand.